Company Profile
What's New
Product Information
Applications Info
Tech Reference List
Information Request
Contact Us
Careers
Email Newsletter
Frequently Asked Questions
In Vitro Basics
In Vitro Toxicology Testing (Non-Animal Safety Testing)
Nanoparticle Research Using MatTek Human Tissue Constructs
Site Map
Search




MatTek Corporation
200 Homer Avenue
Ashland, MA  01721
508-881-6771
FAX:  508-879-1532
E-mail Us

Reproducibility Guaranteed!
Front page
Search

EpiOral™ Excels in P&G Oral Care Formulations Study

To be presented at the International Association of Dental Research Annual Meeting, abstract #1189, Baltimore, MD (March 2005).

Title:

Novel in vitro Methodology Evaluating Potential Mucosal Irritation of Oral Care Formulations. L.A. Bacca*, Procter & Gamble Co., Mason, Ohio; E. A. Jewell-Motz, Procter & Gamble Co., Mason, Ohio

Abstract:

Background: Oral irritation/tissue desquamation can result from exposure of the soft tissue to some dentifrice/rinse formulations. The potentially corrosive effects of common excipients, such as SLS, are well documented. As manufacturers develop products utilizing new actives or combinations of excipients and actives, testing methodology is needed to evaluate the irritation potential of these formulations and ingredients prior to human exposure.

Objective: To develop in vitro methodology for the determination of potential oral irritation of oral care excipients/formulations.

Methods: in vitro tissue models (EpiOral, MatTek Corp.) of human oral keratinocytes were exposed to varying concentrations of common oral care excipients and dentifrice supernatants. These include SLS, poloxamer, NaF dentifrice, and pyrophosphate (PPi)/NaF dentifrices. As a measure of mucosal corrosivity, cell viability levels were monitored over time (up to 24 hrs) via the MTT assay. ET-50 values were calculated. IL1-β and IL1-α profiles were also monitored via ELISA. Correlations were made to in vivo human desquamation testing.

Results: SLS solutions (0.2% to 0.6%) provided a clear dose response in both cell viability and cytokine levels. ET-50 values ranged from 10.5 to < 2 hrs. A dose response was observed for expressed levels of IL1-α and IL1-β. Addition of poloxamer to SLS solutions increased cell viability levels to the range of >24 to 9 hrs, and decreased levels of expressed cytokines. Treatments of NaF and PPi/NaF dentifrices (10% supernatants) exhibited differences for both ET-50 values and cytokine expression levels. These results are consistent and correlate with in vivo oral desquamation testing. Additionally, cell viability results provide a strong correlation to cytokine expression levels.

Conclusions: The in vitro tissue models provide a quick, reproducible method for evaluating the irritation potential of oral care excipients and prototype formulations. The methodology correlates well to human irritation results, and can provide a reliable alternative to animal testing.


Recent MatTek Press Releases
GlaxoSmithKline's Use of EpiAirway in Cigarette Smoke Exposure Research
ERGECD 2008 European Research Group on Experimental Contact Dermatitis 21st Meeting, 24-26th April 2008 London, UK
Linz 2008 - 15th Congress on Alternatives to Animal Testing
ESTIV 2008 - European Society of Toxicology In Vitro
EUROTOX 2008 45th Congress of the European Societies of Toxicology October 5-8 Rhodes, Greece
In Vitro Model for Allergen Screening using Gene Expression Microarray Technology
The FACTS: EpiDerm and ECVAM - Skin Irritation Validation
EpiAirway Performs Well in Inhaled Drug Delivery Experiments
EpiDerm Approved by EU, U.S. Regulators
MatTek Presentations - ZEBET 20th Anniversary International Symposium
New MatTek Technical References January 2009
EpiDerm™ Excels in European (EC) Standards Study
American Association of Pharmaceutical Scientists (AAPS) - 2008 Meeting Presentations
EpiDerm™ Reproducibility The Best Again!
MatTek Presentations - Society of Toxicology (SOT) Meeting March 2009
New MatTek Technical References February 2010
New MatTek Technical References March 2009
Assessment of Human Skin Irritation: Validation of In Vitro Models
EpiAirway™ - Reproducible Pre-Clinical Drug Development Tool
MatTek Presentations - American Thoracic Society (ATS) 2009 Annual Meeting May 15-20, 2009 San Diego, CA (USA)
New MatTek Technical References April 2009
Drug Delivery Research Tools - Recent MatTek Advances
New MatTek Technical References May 2009
Purified Total RNA
MatTek Presentations - Society for In Vitro Biology (SIVB) Annual Meeting June 2009
New MatTek Technical References June 2009
Wall Street Journal Article - MatTek's Human Tissue Models
MatTek Presentations - 7th World Congress on Alternatives & Animal Use in the Life Sciences (WC7)
New MatTek Technical References November 2009
New MatTek Technical References July 2009
EUROTOX 2009 46th Congress of the European Societies of Toxicology September 13-16 Dresden, Germany
EpiOral™ Excels in P&G Oral Care Formulations Study
New MatTek Technical References September 2009
MatTek Presentation - 2005 ATS Meeting
New MatTek Technical References January 2010
New MatTek Technical References December 2009
New MatTek Technical References October 2009
MatTek Presentations – Society of Toxicology (SOT) Meeting March 2011
MatTek Presentation - American Thoracic Society (ATS) 2006 Annual Meeting May 19-24, 2006 San Diego, CA (USA)
MatTek Presentation - 2006 AAPS National Biotechnology Conference June 18-21, 2006
MatTek Presentations - EUROTOX 2006 September 20-24 Cavtat and Dubrovnik, Croatia
MatTek Presentations - Society of Toxicology (SOT) Meeting March 2007
MatTek Presentation - American Thoracic Society (ATS) 2007 Annual Meeting May 18-23, 2007
MatTek Presentations - 6th World Congress on Alternatives & Animal Use in the Life Sciences (WC6)
Tenth International Workshop on Langerhans Cells
Linz 2007 - 14th Congress on Alternatives to Animal Testing
MatTek Presentations - EUROTOX 2007 October 7-10 Amsterdam, The Netherlands
MatTek Presentation - Photosafety Evaluation of Drugs November 21-22 Amsterdam, The Netherlands
MatTek Presentations - Society of Toxicology (SOT) Meeting March 2008
Asthmatic, Smoker, COPD EpiAirway Tissues
Top